Anika Therapeutics, Inc.
ANIK
$9.01
-$0.14-1.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 47.75% | 54.60% | 58.24% | -296.83% | -234.53% |
| Total Depreciation and Amortization | -53.76% | -54.14% | -55.62% | -30.93% | -21.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.91% | -52.05% | -45.72% | 526.83% | 379.06% |
| Change in Net Operating Assets | 77.09% | 59.76% | 11.50% | -11.37% | 37.37% |
| Cash from Operations | -47.39% | 124.00% | 313.70% | 250.84% | 202.37% |
| Capital Expenditure | 29.32% | -27.32% | -18.43% | -35.17% | -10.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 91.23% | 39.33% | -29.48% | -44.98% | -10.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.25% | -45.02% | -41.18% | -29.14% | -29.14% |
| Repurchase of Common Stock | -139.33% | -40.57% | -9.93% | -9.72% | 44.14% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -193.46% | -50.92% | -16.62% | -17.24% | 69.98% |
| Foreign Exchange rate Adjustments | 439.06% | 1,127.78% | 3.80% | 339.39% | -585.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.69% | 9.53% | 22.00% | 51.63% | 91.46% |